Progression free survival in patients treated with cetuximab for unresectable or metastatic hepatocellular carcinoma 2 years [clinicaltrials_resource:49c661c853ce14c2ddafe6e6f4dd0933]
The initial dose of cetuximab was 400 mg/m2 (cycle 1 only) given intravenously followed by weekly intravenous infusions at 250 mg/m2. Each cycle was defined as 6 consecutive weekly intravenous treatments. Treatment was continued until 1 of the following criteria was met: disease progression per RECIST criteria, unacceptable toxicity, patient refusal, or the need to delay therapy more than 3 weeks.
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
Progression free survival in patients treated with cetuximab for unresectable or metastatic hepatocellular carcinoma 2 years [clinicaltrials_resource:49c661c853ce14c2ddafe6e6f4dd0933]
The initial dose of cetuximab was 400 mg/m2 (cycle 1 only) given intravenously followed by weekly intravenous infusions at 250 mg/m2. Each cycle was defined as 6 consecutive weekly intravenous treatments. Treatment was continued until 1 of the following criteria was met: disease progression per RECIST criteria, unacceptable toxicity, patient refusal, or the need to delay therapy more than 3 weeks.
Bio2RDF identifier
49c661c853ce14c2ddafe6e6f4dd0933
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:49c661c853ce14c2ddafe6e6f4dd0933
measure [clinicaltrials_vocabulary:measure]
Progression free survival in p ...... tatic hepatocellular carcinoma
time frame [clinicaltrials_vocabulary:time-frame]
description
The initial dose of cetuximab ...... lay therapy more than 3 weeks.
identifier
clinicaltrials_resource:49c661c853ce14c2ddafe6e6f4dd0933
title
Progression free survival in p ...... patocellular carcinoma 2 years
@en
type
label
Progression free survival in p ...... 661c853ce14c2ddafe6e6f4dd0933]
@en